CPSE:ZEALBiotechs
Zealand Pharma Index Exit And New IR Lead Reframe Valuation Story
Zealand Pharma (CPSE:ZEAL) has been removed from multiple major S&P indices, affecting its presence in index-tracking portfolios.
The index changes have already taken effect, altering how the company features in benchmark-based investment products.
Separately, Zealand Pharma has appointed Eric Rojas as Vice President and Head of Investor Relations.
Rojas brings experience in investor communications, with a mandate to lead the company’s engagement with the capital markets.
Zealand Pharma...